Due to the growth of the SDRC, the committee have agreed we need to take on additional support to help the SDRC Executive Committee with activity. This support will run until our next Executive Committee election at the end of 2020.
Our first member is Dr Sophie Bradley. Sophie is an LKAS fellow at the University of Glasgow. Read Sophie’s biogrpahy below.
I conducted my PhD studies at the University of Leicester in the laboratory of Professor John Challiss, investigating the molecular pharmacology of allosteric modulators of the Type 5 metabotropic glutamate receptor, a member of the G protein-coupled receptor (GPCR) superfamily. This project was supported by GlaxoSmithKline, which allowed me to spend a period of time working at their laboratories in Harlow. Following a one-year position as a research associate in the Challiss laboratory, working on dopamine receptors, I joined Professor Andrew Tobin’s laboratory at the MRC Toxicology Unit as a career development fellow in 2012. Here my research was focussed on defining the physiological roles and therapeutic potential of targeting muscarinic acetylcholine receptors in neurodegenerative diseases. During this time, I spent three months in the laboratory of Dr. Chris Langmead at the Monash Institute of pharmaceutical Sciences, funded by a Royal Society International Exchanges Scheme. In 2016, I moved to the University of Glasgow as a Lord Kelvin Adam Smith (LKAS) fellow to establish an independent research group within the Institute for Molecular, Cell and Systems Biology, working on GPCRs as therapeutic targets in neurodegeneration.
We would like to thank Sophie for agreeing to take on this role, and we look forward to working with you!
The SDRC Executive Committee are elected from SDRC membership annually. If you would like to know more about when these elections are, become an SDRC member